Company Encyclopedia
View More
name
Electrocore
ECOR.US
electroCore, Inc., a bioelectronic medicine and general wellness company, provides non-invasive vagus nerve stimulation (“nVNS”) technology platform in the United States, the United Kingdom, and internationally. The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania. It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an, app-enabled general wellness product. It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions.
1.380 T
ECOR.USMarket value -Rank by Market Cap -/-

Financial Score

13/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking95/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-337.84%E
    • Profit Margin-47.46%E
    • Gross Margin85.97%A
  • Growth ScoreB
    • Revenue YoY27.90%A
    • Net Profit YoY-11.58%D
    • Total Assets YoY1.74%C
    • Net Assets YoY-111.35%E
  • Cash ScoreC
    • Cash Flow Margin-210.71%D
    • OCF YoY27.90%A
  • Operating ScoreA
    • Turnover1.41A
  • Debt ScoreE
    • Gearing Ratio105.01%E

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    electroCore CEO Daniel S. Goldberger Acquires Common Shares

    Daniel S. Goldberger, CEO of electroCore Inc., has acquired common shares of the company. This information was published by electroCore Inc. via the EDGAR system of the U.S. Securities and Exchange Commission on December 03, 2025. The news was generated by Public Technologies using AI and is for informational purposes only.

    Reuters·
    US
    ECOR
    -1.45%
    Reuters·
    US
    ECOR
    -1.45%

    electroCore's TAC-STIM Device Boosts Performance and Mood in Air Force Trainees

    electroCore Inc. announced a study on its TAC-STIM™ device, showing it improved performance, resilience, and mood in 70 Air Force trainees during Military Qualification Training. The findings will be presented at the AHFE2025 Conference on December 8, 2025.

    Reuters·
    US
    ECOR
    -1.45%
    Reuters·
    US
    ECOR
    -1.45%

    electroCore (NASDAQ:ECOR) CFO Sells $13,385.88 in Stock

    electroCore CFO Joshua Lev sold 2,166 shares for $13,385.88, reducing his position by 8.38%. The stock traded down 1.9% to $5.60. electroCore reported Q3 earnings of ($0.40) per share, missing estimates. Analysts have mixed ratings, with a consensus "Hold" and target price of $25.50. Institutional investors have increased their holdings. electroCore develops non-invasive vagus nerve stimulation technology.

    Market Beat·
    US
    ECOR
    -1.45%
    Market Beat·
    US
    ECOR
    -1.45%

    electroCore CFO Joshua S. Lev Reports Disposal of Common Shares

    Joshua S. Lev, CFO of electroCore Inc., reported the disposal of common shares of the company. The filing is available via EDGAR, the SEC's system. This news is AI-generated by Public Technologies and is for informational purposes only, not financial advice.

    Reuters·
    US
    ECOR
    -1.45%
    Reuters·
    US
    ECOR
    -1.45%

    Electrocore’s Strong Financial Performance and Strategic Growth Initiatives Justify Buy Rating

    Analyst Anthony Vendetti from Maxim Group has maintained a Buy rating on Electrocore, with a price target of $12.00, citing strong financial performance and strategic growth initiatives. The company exceeded revenue expectations for Q3 2025 and raised its revenue guidance. Electrocore's expansion in VA/DoD facilities and a diversified product portfolio, including gammaCore and Quell Fibromyalgia, are expected to drive growth. Management anticipates positive adjusted EBITDA in H2 2026 and cash-flow break-even by 2027, supporting the Buy rating. H.C. Wainwright also reiterated a Buy rating with a $25.00 price target.

    Tip Ranks·
    US
    ECOR
    -1.45%
    Tip Ranks·
    US
    ECOR
    -1.45%
    © 2025 Longbridge｜Disclaimer